313 related articles for article (PubMed ID: 29208204)
1. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
Slatinska J; Slavcev A; Honsova E; Hruba P; Kratochvilova I; Rohal T; Viklicky O
HLA; 2018 Dec; 92 Suppl 2():47-50. PubMed ID: 30168284
[TBL] [Abstract][Full Text] [Related]
5. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
[TBL] [Abstract][Full Text] [Related]
6. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
[TBL] [Abstract][Full Text] [Related]
7. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
9. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
Parajuli S; Joachim E; Alagusundaramoorthy S; Blazel J; Aziz F; Garg N; Muth B; Mohamed M; Mandelbrot D; Zhong W; Djamali A
Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
[TBL] [Abstract][Full Text] [Related]
10. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection.
Lichvar AB; Tremblay S; Leino AD; Shields AR; Cardi MA; Abu Jawdeh BG; Govil A; Kremer J; Cuffy M; Paterno F; Diwan T; Brailey P; Girnita A; Alloway RR; Woodle ES
Transplantation; 2020 Nov; 104(11):2403-2414. PubMed ID: 32000256
[TBL] [Abstract][Full Text] [Related]
11. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
12. Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation.
Nakamura T; Yoshimura N; Akioka K; Shirouzu T; Kawai S; Imanishi Y; Matsuyama T; Harada S; Nobori S; Ushigome H
Transplant Proc; 2019 Jun; 51(5):1365-1370. PubMed ID: 31056246
[TBL] [Abstract][Full Text] [Related]
13. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case Report.
Bahena Méndez J; López Y López LR; Sebastián Díaz MA; Trejo Curiel I; Galindo-Lopéz R; Baca Córdova A; Wasung de Lay M; Vázquez Dávila RA; Zarate Rodríguez PA; Carmona-Escamilla MA
Transplant Proc; 2020 May; 52(4):1123-1126. PubMed ID: 32224016
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
[TBL] [Abstract][Full Text] [Related]
17. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
19. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
20. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
